You searched for "therapy"
Richard Wolf Range Update
Richard Wolf a global business with headquarters in Germany and over a century of tradition and expertise in the field of endoscopy. We develop, manufacture and market specific system solutions for minimally invasive human medicine.
Long-term complications of bulking agents in the treatment of SUI
Incontinence poses a substantial economic burden on the UK’s NHS, estimated at £536 million in 1999/2000, equivalent to approximately 1.1% of the total NHS spend, for both men and women. Over two decades later, this cost is expected to have...
All biochemical recurrences are equal, but some are more equal than others
Despite significant technological advancements, radical prostatectomy (RP) and radiotherapy (RT) are not always effective in curing localised prostate cancer (PCa). Many patients experience a rise in prostate-specific antigen (PSA), known as biochemical recurrence (BCR), leading to considerable anxiety and a...
Treatment options for renal cell carcinoma
In this issue of European Urology, experts review advancements and challenges in treating renal cell carcinoma (RCC), emphasising the complexity of managing a disease with an expanding array of therapeutic options. Despite significant progress, critical questions remain about treatment sequencing,...Recent developments in bladder cancer – MIBC
This article takes a look back over recent years at new innovations and developments relating to muscle-invasive bladder cancer (MIBC) specifically, and will also touch upon what the future may hold. This article is also written as a continuation of...Metabolic screening and stone-prevention in urolithiasis patients
The incidence and prevalence of kidney stones is increasing [1,2]. Significant recurrence rates are noted with 14% of patients experiencing a further episode at one year, 35% at five years, and 52% at 10 years [3]. Over 10% of stone...Dietary citrate substitution in urolithiasis patients
Stone formation is dependent on supersaturation of urinary salts and urinary crystal retention. Urinary promoters (protein aggregates, cell debris) and inhibitors (citrate, magnesium, urinary macromolecules such as glycosaminoglycans and proteins) are involved in the process of stone formation [1]. Hypocitraturia...
An Insider’s Perspective of Prostate Cancer – Understanding Effects, Management Options and Consequences
This deceptively small paperback punches way above its weight compared to some of the existing hefty tomes on prostate cancer. It is an admirable effort at delivering content pitched at both the lay reader as well as the medical graduate....
Urinary Stones – Medical and Surgical Management
This book is nicely adapted to cover both the medical and surgical management of urinary stone disease. Those chapters dealing with the surgical management of stone disease are dealt with unsurprisingly well – delivered with a relaxed and conversational prose...
Non-urothelial tumours of bladder – impact on oncological outcomes
Non-urothelial bladder tumours are not very common and they are generally considered to be high risk tumours when compared to standard urothelial tumours. In this study the researchers analysed the oncological outcomes of patients with such histology in comparison to...
Incidence and risk factors of suicide after a prostate cancer diagnosis
This is an observational study looking at 1,281,393 men diagnosed with prostate cancer and 842,294 matched prostate cancer-free men. There was an overall increased relative risk of suicide of 2.01 in men diagnosed with prostate cancer compared to those without,...
